Eligible Registrants – AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Endocrine-Related Cancer Research

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8
Chairperson
Nicholas Mitsiades
Baylor College of Medicine,
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Clinical relevance of comprehensive genomic analysis in patients with advanced-stage neuroendocrine neoplasms: Results from the MASTER trial of the German Cancer Consortium
Simon Kreutzfeldt
National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
p97/VCP: A novel interactor of the sodium iodide symporter, which can be pharmacologically targeted to increase radioiodine uptake in thyroid and breast cancer cells
Alice Fletcher
University of Birmingham, Birmingham, United Kingdom
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Novel clinical targets revealed by kinome reprogramming in mutant ESR1 metastatic breast cancer
Derek Dustin
Baylor College of Medicine, Houston, TX, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER
Tinya J Abrams
Novartis, Cambridge, MA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
FOXA1 chromatin binding is regulated by LSD1-mediated methylation in prostate cancer cells
Changmeng Cai
University of Massachusetts Boston, Boston, MA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
The androgen receptor antagonist darolutamide shows strong antitumor efficacy in patient- and cell line-derived xenograft prostate cancer models
Bernard Haendler
Bayer AG, Berlin, Germany
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
PDX models of ER+ endocrine-resistant metastatic breast cancer identify Polo-like kinase 1 (PLK1) as a therapeutic target
Elisabetta Marangoni
Inst. Curie, Paris, France
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8